Wakix (pitolisant) — Point32Health
narcolepsy with cataplexy
Initial criteria
- Prescribed by or in consultation with a neurologist or sleep specialist
- For adults age ≥ 18 years: documented diagnosis of narcolepsy with cataplexy OR excessive daytime sleepiness associated with narcolepsy AND EITHER (inadequate response, adverse reaction, or contraindication to ALL of: modafinil OR armodafinil, stimulant medication, Sunosi) OR (new to plan and stable on Wakix ≥ 2 months prior to enrollment, excluding samples)
- For pediatric age 6–17 years: documented diagnosis of excessive daytime sleepiness associated with narcolepsy AND trial and failure, inadequate response, intolerance, or contraindication to one stimulant medication
Reauthorization criteria
- Documentation that patient experienced improvement from baseline based on a decrease in frequency of cataplexy attacks OR reduction in daytime sleepiness
Approval duration
12 months